Gilead Hopes To Dodge New Trial With Cystic Fibrosis Antibiotic
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Complete response letter for Cayston (aztreonam) requests another study, but Gilead is talking with FDA to see if re-analysis of existing data will suffice